Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 13/20 | 0.80 |
| ▸ | TNKS | O95271 | 1/20 | 0.59 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.59 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.59 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.59 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.59 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.59 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762553 | 0.89 | PARP1 (1.00) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL8290025 | 0.86 | PARP1 (0.64) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL14028586 | 0.81 | PARP1 (0.58) | PARP1NPC1RAB9A | |
| SCHEMBL7197409 | 0.76 | PARP1 (0.57) | PARP1 | |
| SCHEMBL2764191 | 0.76 | PARP1 (0.81) | PARP1 | |
| SCHEMBL6080430 | 0.75 | PARP1 (1.00) | PARP1NPC1RAB9A | |
| Pj34 SCHEMBL422317 | 0.74 | PARP1 (1.00) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL29375455 | 0.74 | PARP1 (1.00) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL29355630 | 0.74 | PARP1 (1.00) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL4066767 | 0.74 | PARP1 (0.82) | PARP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420785-B1 | SUBSTITUTED INDENO [1,2-C]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-1420785-B1 | SUBSTITUTED INDENO [1,2-C]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2174659-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and uses thereof | Inotek Pharmaceuticals Corporation (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-2174659-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and uses thereof | Inotek Pharmaceuticals Corporation (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-2033645-A1 | Isoquinoline derivatives and methods of use thereof | Inotek Pharmaceuticals Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-7393955-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393955-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| US-20050282848-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-12-22 | — | — | US | disclosed |
| US-6956035-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050049270-A1 | Isoquinoline derivatives and methods of use thereof | JAGTAP PRAKASH (US) | 2005-03-03 | — | — | US | disclosed |
| CN-1575172-A | Substituted indeno [1, 2-c ] isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORP (US) | 2005-02-02 | — | — | CN | disclosed |
| US-6828319-B2 | Antiinflamamtory agents; strokes; cardiovascular disorders | INOTEK PHARMACEUTICALS CORPORATION | 2004-12-07 | — | — | US | disclosed |
| EP-1420785-A2 | SUBSTITUTED INDENO 1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2004-02-26 | — | — | US | disclosed |
| US-20030171392-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-09-11 | — | — | US | disclosed |
| WO-2003020700-A2 | SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020700-A2 | SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | CYP3A7, CYP3A5, ABCG2 | PARP1 363/4885TNKS 371/4885PARP15 112/4885 |
| US-20030171392-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | CYP1B1, UGT1A1, CYP4B1 | PARP1 337/4885TNKS 620/4885PARP15 326/4885 |
| US-20050282848-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | PARP1 363/4885TNKS 371/4885PARP15 112/4885 |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | PARP1 363/4885TNKS 371/4885PARP15 112/4885 |
| US-20050049270-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | PARP1 363/4885TNKS 371/4885PARP15 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.